̽»¨¾«Ñ¡

Joakim Dahlin

Principal Researcher | Docent
Visiting address: Center for Molecular Medicine (CMM) L8, Visionsgatan 18, 17164 Stockholm
Postal address: K2 Medicin, Solna, K2 Imm o lung Nilsson G Dahlin J, 171 77 Stockholm

Articles

  • Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2024;99(1):e13333
    Rosell A; Karlstrom C; Dahlin JS; Boey D; Klimkowska M; Ax K; Thalin C; Ungerstedt J
  • Article: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2023;152(1):205-213
    Soderlund S; Boey D; van Midden W; Kjellander M; Ax K; Qian H; Dahlin JS; Ungerstedt J
  • Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1151754
    Ronnberg E; Ravindran A; Mazzurana L; Gong Y; Safholm J; Lorent J; Dethlefsen O; Orre A-C; Al-Ameri M; Adner M; Dahlen S-E; Dahlin JS; Mjosberg J; Nilsson G
  • Article: BLOOD ADVANCES. 2022;6(15):4439-4449
    Wu C; Boey D; Bril O; Grootens J; Vijayabaskar MS; Sorini C; Ekoff M; Wilson NK; Ungerstedt JS; Nilsson G; Dahlin JS
  • Article: FRONTIERS IN IMMUNOLOGY. 2022;13:902881
    Gao Y; Alisjahbana A; Boey DZH; Mohammad I; Sleiers N; Dahlin JS; Dahlin S; Willinger T
  • Article: FRONTIERS IN IMMUNOLOGY. 2022;12:804812
    Ronnberg E; Boey DZH; Ravindran A; Safholm J; Orre A-C; Al-Ameri M; Adner M; Dahlen S-E; Dahlin JS; Nilsson G
  • Article: ALLERGY. 2021;76(6):1731-1742
    Hamey FK; Lau WWY; Kucinski I; Wang X; Diamanti E; Wilson NK; Gottgens B; Dahlin JS
  • Article: FRONTIERS IN IMMUNOLOGY. 2020;11:321
    Salomonsson M; Dahlin JS; Ungerstedt J; Hallgren J
  • Article: ALLERGY. 2020;75(1):211-214
    Grootens J; Ungerstedt JS; Wu C; Levedahl KH; Nilsson G; Dahlin JS
  • Article: CLINICAL AND EXPERIMENTAL ALLERGY. 2019;49(6):874-882
    Salomonsson M; Malinovschi A; Kalm-Stephens P; Dahlin JS; Janson C; Alving K; Hallgren J
  • Article: EBIOMEDICINE. 2019;43:150-158
    Grootens J; Ungerstedt JS; Ekoff M; Ronnberg E; Klimkowska M; Amini R-M; Arock M; Soderlund S; Mattsson M; Nilsson G; Dahlin JS
  • Article: GENOME BIOLOGY. 2019;20(1):59
    Wolf FA; Hamey FK; Plass M; Solana J; Dahlin JS; Gottgens B; Rajewsky N; Simon L; Theis FJ
  • Article: FRONTIERS IN IMMUNOLOGY. 2018;9:2193
    Ravindran A; Ronnberg E; Dahlin JS; Mazzurana L; Safholm J; Orre A-C; Al-Ameri M; Peachell P; Adner M; Dahlen S-E; Mjosberg J; Nilsson G
  • Article: BLOOD. 2018;131(21):e1-e11
    Dahlin JS; Hamey FK; Pijuan-Sala B; Shepherd M; Lau WWY; Nestorowa S; Weinreb C; Wolock S; Hannah R; Diamanti E; Kent DG; Gottgens B; Wilson NK
  • Article: BLOOD. 2017;130(16):1785-1794
    Dahlin JS; Ekoff M; Grootens J; Lof L; Amini R-M; Hagberg H; Ungerstedt JS; Olsson-Stromberg U; Nilsson G
  • Article: SCIENTIFIC REPORTS. 2017;7(1):623
    Lof L; Arngarden L; Olsson-Stromberg U; Siart B; Jansson M; Dahlin JS; Thorn I; Christiansson L; Hermansson M; Larsson A; Ahlstrand E; Walinder G; Soderberg O; Rosenquist R; Landegren U; Kamali-Moghaddam M
  • Article: FRONTIERS IN IMMUNOLOGY. 2017;8:310
    Zarnegar B; Mendez-Enriquez E; Westin A; Soderberg C; Dahlin JS; Gronvik K-O; Hallgren J
  • Article: SCIENTIFIC REPORTS. 2016;6:28290
    Ding Z; Dahlin JS; Xu H; Heyman B
  • Article: BLOOD. 2016;127(4):383-391
    Dahlin JS; Malinovschi A; Ohrvik H; Sandelin M; Janson C; Alving K; Hallgren J
  • Article: STEM CELLS AND DEVELOPMENT. 2015;24(14):1703-1711
    Dahlin JS; Ding Z; Hallgren J
  • Article: JOURNAL OF IMMUNOLOGY. 2014;193(10):4783-4789
    Cui Y; Dahlin JS; Feinstein R; Bankova LG; Xing W; Shin K; Gurish MF; Hallgren J
  • Article: ALLERGY. 2013;68(10):1333-1337
    Dahlin JS; Heyman B; Hallgren J
  • Article: JOURNAL OF IMMUNOLOGY. 2012;189(8):3869-3877
    Dahlin JS; Feinstein R; Cui Y; Heyman B; Hallgren J
  • Article: SCANDINAVIAN JOURNAL OF LABORATORY ANIMAL SCIENCE. 2012;39(1):11-15
    Dahlin J; Kanui TI; Wambugu SN; Abelson KSP
  • Article: PLOS ONE. 2011;6(7):e21760
    Henningsson F; Ding Z; Dahlin JS; Linkevicius M; Carlsson F; Gronvik K-O; Hallgren J; Heyman B
  • Article: PLOS ONE. 2011;6(5):e20261
    Dahlin JS; Ivarsson MA; Heyman B; Hallgren J
  • Article: SCANDINAVIAN JOURNAL OF LABORATORY ANIMAL SCIENCE. 2009;36(2):205-213
    Dahlin J; Lam J; Hau J; Astuti P; Siswanto H; Abelson KSP
  • Show more

All other publications

  • Letter: BLOOD ADVANCES. 2024;8(15):3941-3945
    Mo J; Wermeling F; Nilsson G; Dahlin JS
  • Editorial comment: BLOOD. 2024;143(11):945-947
    Dahlin JS; Nilsson G
  • Conference publication: EXPERIMENTAL HEMATOLOGY. 2023;124:s41
    Calderbank E; Bastos H; Mantica G; Sham K; Wu C; Dahlin J; Laurenti E
  • Conference publication: EXPERIMENTAL HEMATOLOGY. 2023;124:S41
    Calderbank E; Bastos H; Mantica G; Sham K; Wu C; Dahlin J; Laurenti E
  • Editorial comment: JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2022;32(6):489-491
    Salomonsson M; Cardenas EI; Dahlin JS; Kalm-Stephens P; Janson C; Malinovschi A; Alving K; Hallgren J
  • Conference publication: BLOOD. 2022;140:3014
    Wu C; Boey D; Mo J; Papavasileiou S; Ungerstedt J; Xu M; Nilsson G; Dahlin JS
  • Editorial comment: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2022;150(4):785-787
    Boey D; Nilsson G; Dahlin JS
  • Review: ALLERGY. 2022;77(1):83-99
    Dahlin JS; Maurer M; Metcalfe DD; Pejler G; Sagi-Eisenberg R; Nilsson G
  • Preprint: BIORXIV. 2021
    Wu C; Boey D; Bril O; Grootens J; Vijayabaskar MS; Sorini C; Ekoff M; Wilson N; Ungerstedt J; Nilsson G; Dahlin J
  • Preprint: AUTHOREA PREPRINTS. 2021
    Rönnberg E; Hao DBZ; Ravindran A; Säfholm J; Orre A-C; Al-Ameri M; Adner M; Dahlén S-E; Dahlin J; Nilsson G
  • Preprint: BIORXIV. 2021
    Rönnberg E; Boey DZH; Ravindran A; Säfholm J; Orre A-C; Al-Ameri M; Adner M; Dahlén S-E; Dahlin J; Nilsson G
  • Editorial comment: SCIENCE IMMUNOLOGY. 2021;6(56):eabf7901
    Dahlin JS
  • Preprint: AUTHOREA. 2020
    Dahlin J; Maurer M; Metclafe D; Pejler G; Sagi-Eisenberg R; Nilsson G
  • Preprint: BIORXIV. 2019
    Hamey FK; Lau WWY; Kucinski I; Wang X; Diamanti E; Wilson NK; Göttgens B; Dahlin JS
  • Conference publication: ALLERGY. 2019;74:87
    Hockerlind RE; Dahlin J; Tebroke J; Lieverse J; Ravindran A; Safholm J; Nilsson G
  • Letter: ALLERGY. 2019;74(4):844-845
    Nilsson G; Dahlin JS
  • Review: BLOOD ADVANCES. 2018;2(17):2273-2281
    Grootens J; Ungerstedt JS; Nilsson G; Dahlin JS
  • Preprint: BIORXIV. 2018
    Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini R-M; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
  • Conference publication: EXPERIMENTAL HEMATOLOGY. 2018;64:s70
    Hamey F; Dahlin J; Wolf FA; Pijuan-Sala B; Shepherd M; Lau W; Nestorowa S; Weinreb C; Wolock S; Hannah R; Diamanti E; Theis F; Kent D; Göttgens B; Wilson N
  • Conference publication: EXPERIMENTAL HEMATOLOGY. 2018;64:S70
    Hamey F; Dahlin J; Wolf FA; Pijuan-Sala B; Shepherd M; Lau W; Nestorowa S; Weinreb C; Wolock S; Hannah R; Diamanti E; Theis F; Kent D; Gottgens B; Wilson N
  • Preprint: BIORXIV. 2017
    Wolf FA; Hamey F; Plass M; Solana J; Dahlin JS; Göttgens B; Rajewsky N; Simon L; Theis FJ
  • Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):300
    Avinash R; Hockerlind ER; Dahlin J; Bergman P; Orre A-C; Adner M; Safholm J; Dahlen S-E; Peachell P; Mjosberg J; Nilsson G
  • Letter: LEUKEMIA. 2016;30(9):1953-1956
    Dahlin JS; Ungerstedt JS; Grootens J; Sander B; Guelen T; Haegglund H; Nilsson G
  • Published conference paper: MOLECULAR IMMUNOLOGY. 2015;63(1):9-17
    Dahlin JS; Hallgren J
  • Show more

Grants

  • Swedish Research Council
    1 January 2023 - 31 December 2026
    Significant efforts have been made to map the differentiation of hematopoietic stem and progenitor cells into the various myelo-erythroid cell types. However, the basophil and mast cell differentiation trajectories in human hematopoiesis have yet to be charted in detail. Here, we will leverage single-cell multi-omics approaches with mutation analyses and cell fate assays to resolve a comprehensive roadmap of basophil and mast cell differentiation in health and hematologic disease. This is complemented with high-precision validation experiments, including genetic perturbations of primary cells, to gain mechanistic insights into normal and deregulated hematopoiesis.The research described in this proposal focuses on 1) health, 2) the hematologic neoplasm systemic mastocytosis, driven by the accumulation of aberrant mast cells, and 3) chronic myeloid leukemia, in which basophilia is associated with poor prognosis. My team of experimental and computational researchers combined with well-established clinical collaborations constitute a strong foundation to decipher basophil and mast cell differentiation in these conditions. We hope that the described research contributes to discoveries of novel diagnostic markers and the identification of factors that drive disease development – laying the groundwork for new and improved treatment strategies.
  • Swedish Cancer Society
    1 January 2023
    Mutations in a person's genome can cause a number of different diseases. When mutations arise in blood stem cells and immature blood cells, blood cell development becomes misregulated and diseases such as systemic mastocytosis, myeloproliferative neoplasia, and other types of blood cancer can then occur. Through a combination of the latest techniques, so-called 'single-cell multi-omics', it is now possible to create a clear and almost complete picture of how blood cell development is incorrect in individual patients. The purpose of my research is to create maps of blood cell development for patients with systemic mastocytosis and myeloproliferative neoplasias, above all chronic myeloid leukemia, as well as healthy ones. By generating blood cell maps at diagnosis and during the course of treatment, one can examine the prognosis, see if the treatment has the desired effect and how much of the disease remains. The results of the study facilitate the diagnosis and prognostication of blood cancer, as the blood cell maps of new patients can be compared with previous cases of established blood cancer cases and healthy ones. The hope is that when enough patients are studied, the blood cell maps of newly diagnosed patients can be analyzed to tailor an optimal treatment. Since you will easily see how blood cell development is misregulated upon diagnosis, we hope in the future to be able to find new drugs that restore blood cell development to a normal state.
  • Swedish Cancer Society
    1 January 2020
    Mutations in genes can cause a variety of diseases. When mutations occur in blood stem cells and immature blood cells, blood cell development is misregulated and diseases such as systemic mastocytosis, myeloproliferative neoplasms, and other types of blood cancer can then occur. Diagnosis of patients today requires evaluation of a line samples with a variety of techniques. Through a new technology - so-called "single-cell RNA sequencing" - one can now analyze all genes expressed by tens of thousands of individual immature blood cells. This allows you to quickly get a clear picture of if and how the blood cell development is incorrect in a patient. The purpose of my research is to create maps of blood cell development for patients with systemic mastocytosis and myeloproliferative neoplasms and healthy. By generating blood cell maps at diagnosis and during treatment Once you can see if the treatment has the desired effect and how much of the disease is left. The results of the study facilitate the diagnosis of blood cancer, as new patients' blood cell maps can be compared with previous cases of diagnosed blood cancer cases and healthy. When enough patients are studied, we will come hopefully be able to analyze new patients' blood cell maps to tailor an optimal treatment. Since you will easily see how blood cell development is misregulated at diagnosis, so we hope in the future to be able to find new drugs that restore blood cell development to normal.
  • Swedish Research Council
    1 January 2019 - 31 December 2022
  • Deciphering the transcriptional landscape of mast cell differentiation in systemic mastocytosis and myeloproliferative neoplasms
    Swedish Cancer Society
    1 January 2019
    Mutations in genes can cause a variety of diseases. When mutations occur in blood stem cells and immature blood cells, blood cell development is misregulated and diseases such as systemic mastocytosis, myeloproliferative neoplasms, and other types of blood cancer can then occur. Diagnosis of patients today requires evaluation of a line samples with a variety of techniques. Through a new technology - so-called "single-cell RNA sequencing" - one can now analyze all genes expressed by tens of thousands of individual immature blood cells. This allows you to quickly get a clear picture of if and how the blood cell development is incorrect in a patient. The purpose of my research is to create maps of blood cell development for patients with systemic mastocytosis and myeloproliferative neoplasms and healthy. By generating blood cell maps at diagnosis and during treatment Once you can see if the treatment has the desired effect and how much of the disease is left. The results of the study facilitate the diagnosis of blood cancer, as new patients' blood cell maps can be compared with previous cases of diagnosed blood cancer cases and healthy. When enough patients are studied, we will come hopefully be able to analyze new patients' blood cell maps to tailor an optimal treatment. Since you will easily see how blood cell development is misregulated at diagnosis, so we hope in the future to be able to find new drugs that restore blood cell development to normal.
  • Swedish Research Council
    1 January 2016 - 31 December 2018

Employments

  • Principal Researcher, Department of Medicine, ̽»¨¾«Ñ¡, 2023-

Degrees and Education

  • Docent, ̽»¨¾«Ñ¡, 2024

News from KI

Events from KI